30
total announcements
541540.BO · 15 min delayed
Solara Active Pharma Sciences Ltd
Solara Active Pharma Sciences Ltd has uploaded the audio recording of its Q1 FY27 earnings call held on July 23, 2026, for the quarter ended June 30, 2026, on its website.
Solara Active Pharma Sciences Ltd
Solara Active Pharma Sciences Ltd has submitted a Monitoring Agency Report for the quarter ended June 30, 2026, confirming that there has been no deviation in the utilization of the proceeds of the Rights Issue.
Solara Active Pharma Sciences Ltd
Solara Active Pharma Sciences Ltd has informed the exchange that there is no deviation or variation in the use of proceeds raised through its Rights Issue for the quarter ended June 30, 2026.
Solara Active Pharma Sciences Ltd
Solara Active Pharma Sciences Ltd has informed the Exchange regarding allotment of 2250 Equity Shares pursuant to exercise of ESOP options.
Solara Active Pharma Sciences Ltd
Solara Active Pharma Sciences Ltd has appointed Mr. Ajit Manocha as Chief Information Officer (CIO) with effect from August 10, 2026, as part of the Senior Management Personnel (SMP) of the company.
Solara Active Pharma Sciences Ltd
Solara Active Pharma Sciences Ltd reported strong Q1'27 base business performance with continued growth and profitability. The company's base business revenues stood at INR 3,077 Mn, up 24% YoY, and EBITDA at INR 722 Mn, up 8% YoY, despite input cost pressures resulting from ongoing geopolitical developments in West Asia. The company's overall revenues stood at INR 3,843 Mn, up 20% YoY, and EBITDA at INR 635 Mn, up 10% YoY, and PAT at INR 163 Mn, up 55% YoY, marking the highest EBITDA and PAT reported over the last eighteen quarters.
Solara Active Pharma Sciences Ltd
Solara Active Pharma Sciences Ltd reported strong Q1'27 base business performance with continued growth and profitability. The company's base business revenues stood at INR 3,077 Mn, up 24% YoY, with EBITDA at INR 722 Mn, up 8% YoY. The company's overall revenues stood at INR 3,843 Mn, up 20% YoY, with EBITDA at INR 635 Mn, up 10% YoY, and PAT at INR 163 Mn, up 55% YoY.
Solara Active Pharma Sciences Ltd
Solara Active Pharma Sciences Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with the board of directors approving the results and a limited review report from Deloitte Haskins & Sells.
Solara Active Pharma Sciences Ltd
Solara Active Pharma Sciences Ltd has informed the exchange about the outcome of their board meeting held on July 23, 2026, where they considered and approved the unaudited financial results for the quarter ended June 30, 2026.
Solara Active Pharma Sciences Ltd
Solara Active Pharma Sciences Ltd has announced that Crisil Ratings Limited has upgraded its credit ratings for bank loan facilities totaling Rs. 791.2 Crore. The long-term rating has been upgraded to 'Crisil BBB+/Stable' from 'Crisil BBB/Stable', and the short-term rating has improved to 'Crisil A2' from 'Crisil A3+'. This upgrade reflects an improvement in the company's creditworthiness and financial risk profile.